Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects  by Capone, Marta L. et al.
EP
W
M
E
P
C
A
(
(
p
t
o
a
t
c
t
c
a
C
h
M
C
I
A
2
Journal of the American College of Cardiology Vol. 45, No. 8, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
PXPEDITED REVIEWS
harmacodynamic Interaction of Naproxen
ith Low-Dose Aspirin in Healthy Subjects
arta L. Capone, PHD,*† Maria G. Sciulli, PHD,*† Stefania Tacconelli, PHD,*† Marilena Grana, MD,*†
manuela Ricciotti, PHARMD,*† Giulia Renda, MD,*† Patrizia Di Gregorio, MD,‡ Gabriele Merciaro,‡
aola Patrignani, PHD*†
hieti, Italy
OBJECTIVES We investigated the occurrence of pharmacodynamic interaction between low-dose aspirin
and naproxen.
BACKGROUND The uncertainty of cardioprotection by naproxen has encouraged its combination with aspirin
in patients with arthritis and cardiovascular disease.
METHODS The incubation of washed platelets with naproxen for 5 min before the addition of aspirin
reduced the irreversible inhibition of thromboxane (TX)B2 production by aspirin. The
pharmacodynamic interaction between the two drugs was then investigated in four healthy
volunteers who received aspirin (100 mg daily) for 6 days and then the combination of aspirin
and naproxen for further 6 days: aspirin 2 h before naproxen (500 mg, twice-daily dosing).
After 14 days of washout, naproxen was given 2 h before aspirin for further 6 days.
RESULTS The inhibition of serum TXB2 production (index of platelet cyclooxygenase [COX]-1
activity) and platelet aggregation ex vivo and urinary 11-dehydro-TXB2 levels (index of TXB2
biosynthesis in vivo) by aspirin alone (99 0.2%, 95 0.6%, and 81 4%, respectively) was
not significantly altered by the co-administration of naproxen, given either 2 h after aspirin
or in reverse order. In a second study, the concurrent administration of a single dose of aspirin
and naproxen did not affect platelet TXB2 production and aggregation at 1 h after dosing,
when aspirin alone causes maximal inhibitory effect. Moreover, the rapid recovery of platelet
COX-1 activity and function supports the occurrence of a pharmacodynamic interaction
between naproxen and aspirin.
CONCLUSIONS Naproxen interfered with the inhibitory effect of aspirin on platelet COX-1 activity and
function. This pharmacodynamic interaction might undermine the sustained inhibition of
platelet COX-1 that is necessary for aspirin’s cardioprotective effects. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.0452005;45:1295–301) © 2005 by the American College of Cardiology Foundation
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aspirin and nonaspirin nonsteroidal anti-inflammatory drugs
NANSAIDs) inhibit the synthesis of platelet thromboxane
TX)A2 (the major product of arachidonic acid [AA] in
latelets, serving as potent platelet agonists and vasoconstric-
ors) (1), but only the former has been shown to reduce the risk
f myocardial infarction and stroke (2,3). It generally is
See page 1302
ccepted that the activity of platelet cyclooxygenase (COX)-1,
he COX isoform expressed in platelets (4), has to be almost
ompletely (95%) and continuously inhibited ex vivo
hroughout the dosing intervals to translate into a detectable
ardiovascular protection (1,3,5). This effect can be achieved by
spirin which causes an irreversible inactivation of platelet
OX-1 activity, through a selective acetylation of Ser529 of
uman COX-1 (6,7), which lasts for all platelet lifespan (i.e., 8
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ging, “G. d’Annunzio” University of Chieti, and to Dr. Patrignani (FIRB).c
Manuscript received October 22, 2004; revised manuscript received December 17,
004, accepted January 4, 2005.o 10 days), because the lack of transcription and only scant
ranslation in anucleated platelets (8). In contrast, NAN-
AIDs, which are reversible inhibitors of platelet COX-1,
enerally cause an incomplete and intermittent inhibition of
latelet TXA2, which may be inadequate to prevent cardiovas-
ular events, as shown by the results of epidemiologic studies
3,9–12).
Among NANSAIDs, naproxen recently has gained in-
erest because the results of one randomized clinical trial
13) and several observational studies have suggested its
ossible cardioprotective effect (12,14–16). These results
re consistent with the demonstration that the chronic
dministration of a therapeutic anti-inflammatory dose of
aproxen (500 mg, twice-daily dosing [BID]) to healthy
ubjects causes a persistent and almost-complete suppres-
ion of platelet TXB2 production throughout the 12-h
osing interval (17). However, in other observational stud-
es, naproxen does not affect the risk of cardiovascular events
11,12,18,19). The conflicting results of epidemiologic
tudies reconcile in consideration of the dependence of
etting an almost complete inhibition of platelet COX-1
ctivity ex vivo (95%) at the end of the dosing interval by
reversible inhibitor of COX-1 to translate into cardiovas-ular protection (3). Thus, the use of naproxen in real-life
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either regular nor continuous nor necessarily at high doses
ay explain the variable risk reductions detected.
The uncertainty of a cardioprotective effect by NAN-
AIDs has encouraged their combining with aspirin in
atients with musculoskeletal disorders and vascular disease
20). However, it has been shown recently that the NAN-
AID ibuprofen interferes with the antiplatelet effect of
ow-dose aspirin when they are administered together
21,22). In fact, the stronger binding affinity of NANSAIDs
o Arg120 of the COX-1 channel (a common docking site
or all nonsteroidal anti-inflammatory drugs [NSAIDs],
ncluding aspirin) may prevent the acetylation of Ser529 by
spirin (3,23). In contrast, no interaction is detected in the
o-administration of aspirin with the NANSAIDs acet-
minophen and diclofenac or with the selective COX-2
nhibitor rofecoxib (21).
In the present study, we investigated the occurrence of a
harmacodynamic interaction between low-dose aspirin and
aproxen. First, we assessed the effects of naproxen on the
rreversible inhibition of platelet TXB2 production by aspi-
in in vitro. Then, we studied in healthy subjects the
otential interference of naproxen with aspirin inhibitory
ffects on platelet TXB2 biosynthesis ex vivo and in vivo and
n platelet aggregation ex vivo.
ETHODS
tudy subjects. The study protocol was approved by the
thical committee of “G. d’Annunzio” University of Chieti.
nformed consent was obtained from the nine subjects
nrolled. The subjects were between 23 and 30 years of age
nd within 30% of ideal body weight and had an unremark-
ble medical history, physical examination, and routine
ematological and biochemical studies. Smokers and sub-
ects with a bleeding disorder, an allergy to aspirin or any
ther NSAID, or a history of any gastrointestinal or
erebrovascular disease were excluded. Subjects abstained
rom the use of aspirin and other NSAIDs for at least two
eeks before enrollment.
n vitro study. First, we characterized the nature of the
nteraction (i.e., reversible or irreversible) between aspirin or
Abbreviations and Acronyms
AA  arachidonic acid
BID  twice-daily dosing
CI  confidence interval
COX  cyclooxygenase
IC50  concentrations required to inhibit 50% of
enzyme activity
NANSAIDs  nonaspirin nonsteroidal anti-
inflammatory drugs
NSAIDs  nonsteroidal anti-inflammatory drugs
PG  prostaglandin
TX  thromboxaneaproxen and platelet COX-1 by assessing the capacity of rncreasing concentrations of exogenous AA to overwhelm
he inhibitory effect of TXB2 production by aspirin or
aproxen in washed human platelets. Fresh peripheral blood
rom healthy volunteers who had not taken NSAIDs for 14
ays was collected in Vacutainer tubes without heparin and
as mixed with 10% (vol/vol) anticoagulant solution (65
mol/l citric acid/85 mmol/l sodium citrate/2% glucose,
H 7.4). Washed platelets (1.5  108 cells/ml), prepared as
reviously described (23), were incubated with increasing
oncentrations of aspirin (0.01 to 100 mol/l), naproxen
0.01 to 100 mol/l), or dimethyl sulfoxide vehicle (1 l) for
5 min, and then 0.5 or 10 mol/l of AA (Sigma Chemical
o., St. Louis, Missouri) was added for an additional 30
in at 37°C. To determine whether naproxen inhibited the
cetylation of COX-1 by aspirin, we incubated an increasing
oncentration of naproxen (0.01 to 10 mol/l) with washed
latelets (1.5  108 cells/ml) for 5 min before the addition
f aspirin (10 or 100 mol/l), and the incubation continued
or additional 20 min at 37°C. The cells were washed twice
ith Hanks’ balanced salt solution supplemented with
5 mmol/l HEPES/10% anticoagulant solution to remove
he reversible inhibitor. The platelets were then resuspended
n 500 l of Hanks’ balanced salt solution supplemented
ith 25 mmol/l HEPES, challenged with AA 10 mol/l for
0 min at 37°C, and TXB2 production was determined by
adioimmunoassay (24). Under these experimental condi-
ions, a detectable inhibition of platelet TXB2 production
as dependent on the chance of aspirin to acetylate COX-1.
linical study: Design, treatments, and assessment. The
otential interactions between low-dose aspirin and
aproxen co-administered to four healthy subjects on plate-
et TX biosynthesis in vivo and ex vivo and platelet
ggregation induced by AA (1 mmol/l) ex vivo (25) were
valuated in two different studies (Fig. 1). In the first study,
ncoated aspirin (100 mg daily, at 8 AM) to be swallowed
hole was given for 6 consecutive days, and then the
ombination of aspirin and naproxen was administered for
urther 6 days: aspirin was given 2 h before naproxen (500
g BID, at 10 AM and 10 PM). After a washout period of 14
ays, the treatments were administered in reverse order, i.e.,
ow-dose aspirin (100 mg daily at 10 AM) was taken 2 h after
aproxen (500 mg BID, at 8 AM and 8 PM) for further 6
ays. Blood samples were collected before and at 2, 5, 14,
nd 26 h after the first study drug on the 6th, 12th, 27th,
nd 32nd study day to assess the inhibition of serum TXB2
a capacity index of platelet COX-1 activity) (24) and
ipopolysaccharide-induced prostaglandin (PG)E2 produc-
ion (a capacity index of monocyte COX-2 activity) (26).
hree consecutive urinary samples (time of collection: 0 to
h, 6 to 12 h, and 12 to 24 h) were collected before
reatment and on days 6, 12, 27, and 32 to evaluate the
rinary excretion of 11-dehydro-TXB2 (a major enzymatic
etabolite of TXB2 that is an index of TXA2 biosynthesis
n vivo) (27). In the second study, a single dose of aspirin
100 mg) and naproxen (500 mg) was administered concur-
ently to 5 healthy subjects, and peripheral blood samples
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April 19, 2005:1295–301 Interaction Between Naproxen and Aspirinere collected before and up to 14 days after dosing to assess
he time-dependent inhibition and recovery of serum TXB2
roduction and platelet aggregation ex vivo. Platelet aggre-
ation induced by AA (1 mmol/l) was measured in platelet-
ich plasma (25) using a Chrono-Log platelet aggregometer
Chrono-log Corp., Havertown, Pennsylvania), whereas
mmunoreactive TXB2, PGE2, and 11-dehydro-TXB2 were
easured by previously validated radioimmunoassay tech-
iques (24,26,27).
tatistical analysis. The data are expressed as mean 
EM. Statistical comparisons were made by analysis of
ariance followed by the Student-Newman-Keuls test. A
robability value of p  0.05 was considered to be statisti-
ally significant. The primary hypothesis was that naproxen
500 mg, BID), administered 2 h before aspirin, would
nterfere with the irreversible effects of aspirin, as assessed
y the measurement of serum TXB2 (primary end point)
nd platelet aggregation (secondary end point) 26 h after a
-day dosing of the combined therapy. Assuming an inter-
ubject coefficient of variation of 20% for serum TXB2, four
ubjects would allow detection of a difference of 50%
etween the inhibitory effect by aspirin alone and its
o-administration with naproxen, with a power of 90%, on
he basis of two-tailed tests, with probability values less than
igure 1. Flow chart of study protocols. In the study with multiple daily
oses, aspirin (100 mg daily and once at 8 AM) was administered for 6
onsecutive days and then naproxen (500 mg twice daily, once at 10 AM and
0 PM) was co-administered 2 h after aspirin for further 6 days to 4 healthy
ubjects. After a washout period of at least 14 days, the volunteers reversed
he treatment, i.e., low-dose aspirin (100 mg daily at 10 AM) was
dministered 2 h after naproxen (500 mg twice daily, once at 8 AM and once
t 8 PM) for further 6 days. Blood samples were collected before and up to
6 h after dosing with the first study drug on the 6th, 12th, 27th, and 32nd
tudy day to assess the inhibition of serum thromboxane (TX)B2 (a capacity
ndex of platelet cyclooxygenase [COX]-1 activity) and lipopolysaccharide-
nduced prostaglandin E2 production (a capacity index of monocyte
OX-2 activity). Three consecutive urinary samples (time of collection: 0
o 6 h, 6 to 12 h, and 12 to 24 h) were collected before treatment and on
ays 6, 12, 27, and 32 to evaluate the urinary excretion of 11-dehydro-
XB2 (a major enzymatic metabolite of TXB2 that is an index of TXA2
iosynthesis in vivo). In the study with single dose, aspirin (100 mg) and
aproxen (500 mg) were co-administered to 5 healthy subjects, and
eripheral blood samples were collected before and up to 14 days after
osing to assess the time-dependent inhibition and recovery of serum
XB2 production and platelet aggregation ex vivo.he type I error rate of 0.05. Concentration-response curves fere fitted, and IC50 (concentrations required to inhibit
0% of enzyme activity) values were analyzed with PRISM
GraphPad, San Diego, California). The IC50 values were
eported as mean values, and 95% confidence intervals (CIs)
ere calculated.
ESULTS
harmacodynamic interaction between aspirin and
aproxen in vitro. As shown in Figures 2A and 2B, aspirin
nd naproxen inhibited TXB2 production by washed plate-
ets in a concentration-dependent fashion. However, in
ontrast to aspirin, the potency of naproxen to inhibit
latelet COX-1 activity decreased in the presence of the
igher concentration of AA, which supports the reversible
nteraction of naproxen, but not aspirin, with COX-1. At
.5 and 10 mol/l of AA, aspirin inhibited COX-1 activity,
ith IC50 values of 3.40 mol/l (95% CI 2.70 to 4.30
mol/l) and 4.50 mol/l (95% CI 3.80 to 5.50 mol/l),
espectively, whereas the corresponding values for naproxen
ere 0.16 mol/l (95% CI 0.10 to 0.20 mol/l) and 0.75
mol/l (95% CI 0.50 to 1.20 mol/l), respectively. Exper-
ments were then conducted to determine the ability of
aproxen to affect platelet COX-1 acetylation by aspirin.
latelets were pretreated with naproxen for 5 min before the
ddition of 10 or 100 mol/l of aspirin and incubated for an
dditional 20 min. The cells were then centrifuged and
ashed twice, as described previously, to remove any revers-
ble clogging of COX-1 channel, and then challenged for
XB2 production with 10 mol/l of AA.
Under these experimental conditions, a detectable inhi-
ition of platelet TXB2 production was dependent on the
hance of aspirin to acetylate COX-1. Aspirin alone at 10
nd 100 mol/l inhibited TXB2 production by 73 7% and
9  2%, respectively. The preincubation of platelets with
ncreasing concentrations of naproxen reduced the irrevers-
ble inhibition of TXB2 production by aspirin (Fig. 2C). At
spirin concentrations of 100 mol/l, the naproxen
oncentration-response curve was shifted to the right, sug-
esting that the pharmacodynamic interaction between the
wo drugs involved a competition at the enzyme active site
Fig. 2C). The irreversible inhibition of platelet COX-1 by
spirin was affected by naproxen concentrations lower than
hose blocking platelet COX-1 activity. In fact, it was
etectable at 0.1 mol/l of naproxen (Fig. 2C), which did
ot affect TXB2 production by platelets challenged with 10
mol/l of AA (Fig. 2B).
tudy with multiple daily doses. As shown in Figures 3A
nd 3B, the administration of low-dose aspirin for six
onsecutive days caused an almost complete inhibition of
latelet COX-1 activity and platelet aggregation (99 
.2% and 95  0.6%, respectively, mean  SEM, n  4)
hat persisted up to 26 h after the last dose and was not
ltered by the co-administration of naproxen (2 h after
spirin) or in reverse order (naproxen 2 h before aspirin) for
urther 6 days. The reduction of urinary levels of 11-
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Interaction Between Naproxen and Aspirin April 19, 2005:1295–301ehydro-TXB2 (81  4%, 74  6%, and 83  6%,
espectively) assessed in three consecutive urine collections
0 to 6 h, 6 to 12 h, and 12 to 24 h, respectively) obtained
fter chronic dosing with aspirin alone was not affected by
he concomitant administration of naproxen given 2 h after
spirin (Fig. 3C). A comparable inhibition of the urinary
nzymatic metabolite was found when naproxen was given
h before aspirin (Fig. 3C).
As shown in Figure 4, lipopolysaccharide-induced PGE2
roduction was not significantly affected by the chronic
dministration of low-dose aspirin, whereas it was pro-
oundly inhibited by the concomitant chronic administra-
ion of naproxen given 2 h after aspirin or in reverse order.
tudy with single dose. Because the profound and long-
asting inhibition of platelet COX-1 activity caused by
aproxen (17) might have shaded its possible antagonism on
igure 3. Mean inhibition of platelet cyclooxygenase-1 activity ex vivo, as
ssessed by the measurement of serum thromboxane (TX)B2 levels (A),
rachidonic acid-induced platelet aggregation ex vivo (B), and TX biosyn-
hesis in vivo, as assessed by the measurement of urinary 11-dehydro-TXB2
evels (C), in subjects taking low-dose aspirin alone (100 mg daily) for six
ays (hatched bars) and then readministered with naproxen (500 mg twice
aily, with the first dose administered 2 h after aspirin) for further six days
open bars). The solid bars show the effects of the same medications
dministered in reversed order for further six days after a washout period of
4 days. Values are reported as mean  SEM, n  4. All times are hours
fter the administration of the first study drug. Open bars aspirin before
aproxen (twice daily); solid bars  naproxen (twice daily) before aspirin;
atched bars  aspirin.igure 2. Concentration-response curves for the inhibition of plate-
et cyclooxygenase (COX)-1 activity by aspirin (A) and naproxen (B).
ne-milliliter aliquots of washed platelets (1.5  108 cells) were
reincubated with increasing concentrations of aspirin (0.01 to
00 mol/l) or naproxen (0.01 to 100 mol/l) for 25 min, and then 0.5
r 10 mol/l of arachidonic acid (AA) was added for an additional
0 min at 37°C. In panel C, the antagonism of aspirin inhibition of
latelet COX-1 by naproxen is shown. Increasing concentrations of
aproxen (0.01 to 10 mol/l) were incubated with washed platelets
1.5  108 cells/ml) for 5 min before the addition of aspirin (10 or
00 mol/l) and the incubation continued for additional 20 min at
7°C. After washing twice, platelets were resuspended in 500 l of
anks’ balanced salt solution supplemented with 25 mmol/l HEPES,
hallenged with 10 mol/l of AA for 30 min at 37°C, and thromboxane
TX)B2 levels were determined by radioimmunoassay. The data repre-
ent the average of inhibition of platelet TXB2 production from five
ifferent donors. IC  concentrations required to inhibit 50% ofhe irreversible antiplatelet effect of aspirin, we studied the
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ctivity and AA-induced platelet aggregation up to 14 days
fter the concurrent administration of single doses of aspirin
100 mg) and naproxen (500 mg). The co-administration of
he two drugs caused a time-dependent inhibition of plate-
et COX-1 activity and function (Fig. 5). Interestingly, at
h after dosing, serum TXB2 and platelet aggregation were
ot significantly affected (92  5% and 99  0.1% of
re-drug values, respectively), which suggests that naproxen
oncentrations lower than those inhibiting platelet COX-1
ctivity interfered with the irreversible inhibition of aspirin.
he inhibition of serum TXB2 production and platelet
ggregation recovered in a time-dependent fashion. At 72 h
fter dosing, serum TXB2 and platelet aggregation values
65  12% and 80  19% of pre-drug values, respectively)
id not differ, in a statistically significant fashion, from
hose assessed before (100  11% and 100  0.6% of
re-drug values, respectively) or 14 days after treatment (86
7% and 99  0.7% of pre-drug values, respectively). The
apid recovery of COX-1 activity and function confirmed
he occurrence of the pharmacodynamic interaction be-
ween naproxen and aspirin.
ISCUSSION
everal epidemiologic studies have been performed to es-
ablish the possible antithrombotic effect of naproxen, but
he results did not present a clear picture (9–12,14–
6,18,19). Probably, the administration of the drug not at
igh doses, not continuously and regularly, as occurs in real
ife photographed by the observational studies, may have
ontributed to the unsettled cardioprotective effect of
aproxen. The final say on the risk reduction of myocardial
nfarction by naproxen will be made when prospective
ontrolled trials of adequate size are performed. In the
igure 4. Mean inhibition of monocyte cyclooxygenase-2 activity ex vivo,
rostaglandin (PG)E2 levels in subjects taking low-dose aspirin alone (100 m
g twice daily, with the first dose administered 2 h after aspirin) for a furth
dministered in reversed order for further six days after a washout period of
SEM of inhibition (%) of LPS-induced PGE2 levels caused by the diffe
re hours after the administration of the first study drug. Open bars  as
spirin; hatched bars  aspirin.eantime, patients with musculoskeletal disorders treated
a
cith naproxen should receive low-dose aspirin as well if they
equire an antithrombotic treatment. However, a pharma-
ologic study has shown that the NANSAID ibuprofen, but
ot diclofenac, acetaminophen, or rofecoxib, can antagonize
he irreversible inhibition of platelet TXA2 by aspirin when
hey are administered together (21).
In the present study, we have addressed whether
aproxen might competitively inhibit the ability of aspirin
o cause an irreversible inhibition of platelet COX-1 in
itro, ex vivo, and in vivo in healthy subjects. First, we
haracterized the interaction between aspirin or naproxen
nd platelet COX-1 in washed platelets in vitro. Aspirin
aused an irreversible inhibition of platelet COX-1. In fact,
he inhibition of TXB2 production by aspirin was not
nfluenced by the concentrations of exogenous AA (the
igure 5. Mean inhibition of platelet cyclooxygenase-1 activity ex vivo
solid circles) (as assessed by measurement of serum TXB2) and arachi-
onic acid-induced platelet aggregation ex vivo (open circles) in subjects
aking a single dose of aspirin (100 mg) and naproxen (500 mg). Values are
eported as mean  SEM, n  5. Serum TXB2 and platelet aggregation
ere significantly inhibited versus pre-drug values at 3 h (p  0.01 and
.05, respectively), 12 h (p  0.01), 24 h (p  0.01), and 48 h (p  0.01
nd 0.05, respectively) after dosing. No significant differences were found
essed by measurement of whole-blood lipopolysaccharide (LPS)-induced
ily) for 6 days (hatched bars) and then readministered with naproxen (500
days (open bars). The solid bars show the effect of the same medications,
s, on monocyte cyclooxygenase-2 activity. The values are reported as mean
reatments, n  4. *p  0.05, **p  0.01 versus pre-drug values. All times
before naproxen (twice daily); solid bars  naproxen (twice daily) beforeas ass
g da
er 6
14 day
rent t
pirint 1, 72, 144, 192, and 336 h after dosing versus pre-drug values. Open
ircles  platelet aggregation; solid circles  serum TXB2.
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Interaction Between Naproxen and Aspirin April 19, 2005:1295–301ubstrate of COX-1) (Fig 2A). Differently, naproxen caused
reversible inhibition of COX-1 (Fig. 2B). Next, we
tudied whether the preincubation of naproxen had the
bility to affect the irreversible inhibition of platelet COX-1
y aspirin. We pretreated platelets with naproxen for 5 min
efore the addition of aspirin, and we evaluated the produc-
ion of TXB2 in response to AA after having washed the
ells to remove reversible blockage of COX-1. Under these
xperimental conditions, a detectable inhibition of platelet
XB2 production was dependent on the chance of aspirin to
cetylate COX-1. Naproxen, indeed, reduced the inhibition
f platelet TXB2 production by aspirin in a concentration-
ependent fashion (Fig. 2C). This effect occurred even at
ower drug concentrations than those inhibiting platelet
OX-1 activity. The explanation is that in the first case
aproxen competes with aspirin, which is a weak inhibitor
f platelet COX-1, whereas in the second case the drug
ompetes with AA, which binds the enzyme strongly.
imilar results have been reported for ibuprofen and
OX-2 inhibitors in vitro (23).
After having highlighted a pharmacodynamic interaction
etween aspirin and naproxen in vitro, we verified its
ccurrence ex vivo. The concurrent administration of a
ingle dose of the two drugs to healthy subjects was
ssociated with undetectable inhibition of serum TXB2
roduction at 1 h after dosing. This finding is consistent
ith the interference of naproxen on the irreversible inhi-
ition of platelet COX-1 by aspirin. In fact, it has been
eported previously that the administration of aspirin inhib-
ts platelet COX-1 activity (as assessed by the measurement
f serum TXB2 production) before the drug reaches the
ystemic circulation; this effect is maximal at 20 min after
osing, coinciding with the peak plasma concentrations of
he active drug (28). Despite the short half-life of aspirin
approximately 20 min), the inhibition of platelet COX-1
ctivity persists up to 24 h as the result of irreversible
nzyme inactivation (Fig. 2A) (18).
Similar to that found in vitro, naproxen interfered with
spirin acetylation at concentrations lower than those inhib-
ting platelet COX-1 activity. In fact, circulating plasma
evels of the drug suited to inhibit the platelet enzyme are
eached more than 1 h after dosing since time to reach peak
oncentration in the systemic circulation (Tmax) of naproxen
s 3 to 4 h. The finding of a rapid recovery of platelet TXB2
roduction and platelet aggregation detected after the co-
dministration of a single dose of aspirin and naproxen
orroborates the occurrence of the interaction between
aproxen and aspirin (29). However, the chronic adminis-
ration of naproxen 2 h after aspirin or in reverse sequence
or 6 consecutive days did not affect the inhibition of TXB2
iosynthesis ex vivo and in vivo and platelet aggregation ex
ivo caused by aspirin alone. The most likely explanation of
hese results is that the pharmacodynamic interaction be-
ween the two drugs was shaded because of the capacity of
igh-dose naproxen to mimic the antiplatelet COX-1 effect
f low-dose aspirin (17).However, in our earlier work, we found that even within
he context of a controlled and well-monitored study, the
hronic administration of naproxen 500 mg BID gets into
he functionally relevant range, i.e., 95% inhibition of
latelet COX-1 activity ex vivo at the end of the dosing
nterval, in some but not all subjects (17). Such heteroge-
eity, as well as departure from the rigor of monitored drug
ntake, might explain the weak and irregular signal of
ardioprotection from naproxen in epidemiologic analyses
19,22,30). We cannot assess whether naproxen heteroge-
eity occurred in the present study because of the back-
round of aspirin; perhaps in those subjects in whom
unctional inhibition of COX-1 was not attained by
aproxen, a partial contribution was afforded by aspirin.
nother limitation is the small sample size, which allowed
s to discern only large differences and did not enable us to
ssess the impact of other covariates such as gender and age.
onclusions. Naproxen interfered with the irreversible
nhibitory effect of aspirin on platelet COX-1 activity in
itro and ex vivo. This effect was undetectable during the
ontinuous and regular administration of an anti-
nflammatory dose of naproxen (500 mg BID) and low-dose
spirin because naproxen can mimic the inhibitory effect of
spirin on platelet TXA2 generation. However, in the real
orld, naproxen combination with aspirin might undermine
he sustained inhibition of platelet COX-1 necessary for
ardioprotection from aspirin.
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